ASCENSIA DIABETES CARE ANNOUNCES GLOBAL INTEGRATION OF CGM EVERSENSE WITH APPLE HEALTH

10 November 2022

Ascensia Diabetes Care, a global diabetes product company, manufacturer of CONTOUR Glucose Monitoring System (BGM) and distributor of Eversense  Continuous Glucose Monitoring (CGM), announces the Eversense App   CGM has received a global update allowing for seamless integration with the Apple Health TM system . As a result, people with diabetes who use Eversense CGM systems will now be able to view their blood glucose data in the Apple Health app along with other health metrics from this popular iPhone health and wellness tracking platform.

Developed by Senseonics Holdings Inc. (NYSE American: SENS), the ultra-accurate and fully implantable Eversense E3 system is the longest-lasting CGM sensor available, with a lifespan of up to 6 months. The system uploads data to the Eversense CGM App, where users can easily track, analyze and share glucose data with notifications of changes and trends. With this update, users in all markets where Eversense is available can now view their data in the Apple Health app, where they can also view other health data collected by their iPhone through a variety of wearable apps and devices.

"We are delighted to be able to integrate the Eversense CGM System with the Apple Health App , giving our users more choice when it comes to viewing and using diabetes-related data," said Elaine Anderson , director of the Eversense CGM business unit, Ascensia Diabetes Care. - The update complements the benefits of the Eversense CGM App as it allows people with diabetes to access glycemic data along with other important metrics, giving them a more holistic view of their health and well-being. In an increasingly digital world, there is a strong need for medical devices and digital solutions to work together, so we are excited to be able to integrate Eversense into a connected health monitoring ecosystem. "

Ascensia Diabetes Care enables patients to access the power of information, data and advanced analytics, and works with Senseonics to make the Eversense system compatible with more digital diabetic devices and platforms. Together, the two companies endeavor to approve the iCGM (Integrated CGM System) system and its connection to Automatic Insulin Delivery (AID) systems, as well as actively seeking industry partners to help the diabetic community maximize the benefits of the Eversense System.

Eversense CGM Systems and the Eversense CGM App are available in the US and Europe. Visit www.ascensia.com/eversense for more information.

Logo - https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.webp


SOURCE Ascensia Diabetes Care

 

Source:prnewswire.com

ASCENSIA DIABETES CARE ANNOUNCES GLOBAL INTEGRATION OF THE EVERSENSE CGM SYSTEM WITH APPLE HEALTH

7 November 2022

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR Blood Glucose Monitoring (BGM) System portfolio and distributor of the Eversense Continuous Glucose Monitoring (CGM) System, announces that the Eversense CGM app has been updated globally to seamlessly integrate with Apple Health. This means that people with diabetes using Eversense CGM Systems will now also have the option to view their glucose data within the Apple Health app, alongside other health metrics on the iPhone's widely used health and wellbeing platform.

Developed by Senseonics Holdings, Inc. (NYSE American: SENS), the exceptionally accurate and fully-implantable Eversense E3 is the longest-lasting CGM available, with up to a 6-month sensor wear duration. The system transmits data to the Eversense CGM App where users can easily view, analyse and share glucose data, and are alerted to changes and trends. With this update, users in all markets where Eversense is available can now choose to display their data in Apple Health, where they will also be able to view health data collected by their iPhone through various apps and wearables. This integration aims to improve diabetes management by allowing Eversense users to easily view their glucose data within their wider digital health environment.

"We are pleased to integrate the Eversense CGM system with Apple HealthTM, giving our users more choice on how they view and use data for their diabetes management," said Elaine Anderson, Head of the Eversense CGM Business Unit at Ascensia Diabetes Care. "Supplementing the benefits of the Eversense CGM App, this update allows people with diabetes to access glucose data alongside other important metrics to provide a more holistic view of their health and wellbeing. In an increasingly digital world, it is important that medical devices and digital solutions are interoperable, and we are excited to further embed Eversense into the connected healthcare ecosystem."

Ascensia Diabetes Care is committed to putting the power of information, data and advanced analytics in the hands of patients and is working alongside Senseonics to make Eversense interoperable with more diabetes devices and digital platforms. Together, the companies are executing plans to achieve iCGM (integrated CGM) approval and integration with automated insulin delivery (AID) systems, as well as actively seeking industry collaborations that will maximize the benefits of Eversense for the diabetes community.

Eversense CGM Systems and the Eversense CGM App are available across the US and Europe. Please visit www.ascensia.com/eversense for more information.

Logo - https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.webp

 

Source:prnewswire.com